Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Improvement of hyperandrogenic alopecia in women after 1-year treatment with flutamide

Feb. 5, 2003

First biologic therapy for psoriasis approved by FDA

Feb. 4, 2003

BioTransplant and Catholic University of Louvain attempt to resolve dispute regarding MEDI-507

Feb. 4, 2003

Catholic University of Louvain to terminate agreement with BioTransplant

Feb. 3, 2003

Toray and Fujisawa to codevelop TRK-820 in Europe

Feb. 3, 2003

MBI-594AN enters phase IIb for treatment of acne

Jan. 31, 2003

Naltrexone well tolerated and effective in pruritus caused by cholestasis

Jan. 28, 2003

Two courses of alefacept evaluated in patients with chronic plaque psoriasis

Jan. 24, 2003

QRX-101 phase II trial in psoriasis cleared to begin

Jan. 24, 2003

Efficacy of TAK-427 in experimental model of atopic dermatitis

Jan. 23, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.